Lymphocyte Immunophenotyping in Common Variable Immunodeficiency
Maneno muhimu
Kikemikali
Maelezo
Common Variable Immune Deficiency (CVID) is a syndrome containing a spectrum of disorders which results in weakened immunity and recurrent infections. The ESID (European Society for Immunodeficiencies) CVID definition includes patients with marked decrease of IgG (at least 2 standard deviations below the mean for age). Patients must also have disease onset at an age over 2 years, absent isohaemagglutinins and/or response to vaccines and other defined causes of hypogammaglobulinaemia must be excluded. The Euroclass system of classifying CVID is the result of a European multicentre trial attempting to develop a consensus of two existing classification schemes of B-cell immunophenotyping. In this paper it was shown that B-cell immunophenotype correlated with coincidence of clinical sequelae and it suggested implementing this to further classify CVID to give prognostic and therapeutic information. However, it has not yet been shown that these alterations in B-cell immunophenotype are the result of CVID itself and not caused by the treatment or complications of CVID (e.g. immunoglobulin replacement therapy, granulomatous disease, bronchiectasis). The aim of this study is to show that alterations in B-cell immunophenotype are caused by CVID itself and not by its complications or treatment. The study will therefore compare CVID patients to suitable control patients with granulomatous disease, bronchiectasis and on long-term immunoglobulin therapy. A control group of normal people will also be included to ensure the assay can detect normality and to show differences between normal people and patients with CVID.
Tarehe
Imethibitishwa Mwisho: | 08/31/2010 |
Iliyowasilishwa Kwanza: | 09/05/2010 |
Uandikishaji uliokadiriwa Uliwasilishwa: | 09/06/2010 |
Iliyotumwa Kwanza: | 09/07/2010 |
Sasisho la Mwisho Liliwasilishwa: | 09/06/2010 |
Sasisho la Mwisho Lilichapishwa: | 09/07/2010 |
Tarehe halisi ya kuanza kwa masomo: | 02/28/2010 |
Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 05/31/2010 |
Tarehe ya Kukamilisha Utafiti: | 06/30/2011 |
Hali au ugonjwa
Awamu
Vikundi vya Arm
Mkono | Uingiliaji / matibabu |
---|---|
CVID Patients with common variable immunodeficiency | |
CVID and granulomatous disease Patients with CVID complicated with granulomatous inflammation | |
CVID and bronchiectasis Patients with CVID complicated by bronchiectasis | |
Control on Immunoglobulin Patients on immunoglobulin long-term who do not have an immunodeficiency | |
Control bronchiectasis Controls with bronchiectasis not caused by a known immunodeficiency | |
Control with granulomatous disease Control patients with Crohn's Disease as this is a disease that causes granulomatous inflammation. | |
Healthy Controls |
Vigezo vya Kustahiki
Zama zinazostahiki Kujifunza | 18 Years Kwa 18 Years |
Jinsia Inastahiki Kujifunza | All |
Njia ya sampuli | Non-Probability Sample |
Hupokea Wajitolea wa Afya | Ndio |
Vigezo | Inclusion Criteria: - 18 or over - Competent to consent - Have diagnosis of Common Variable Immunodeficiency, granulomatous disease, on long term immunoglobulin or bronchiectasis. Exclusion Criteria: - Under 18 - Unable to consent. - Medical problem that could alter B-cell immunophenotype (except for the diagnoses in the inclusion criteria)/ |
Matokeo
Hatua za Matokeo ya Msingi
1. Percentage of B-cells of all lymphocytes [5 months]
2. Percentage of class switched memory B-cells as a percentage of B-cells [5 months]
Hatua za Matokeo ya Sekondari
1. Percentage expression of CD21 and CD38 [5 months]